Ascendis Pharma to Directly List Ordinary Shares on Nasdaq, Mandating ADS Exchange

summarizeSummary

Ascendis Pharma announced plans to directly list its ordinary shares on The Nasdaq Global Select Market, effective April 20, 2026, requiring a mandatory exchange of all outstanding American Depositary Shares (ADSs) for ordinary shares.

check_boxKey Events

• Direct Nasdaq Listing

  Ascendis Pharma plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective April 20, 2026.

• Mandatory ADS Exchange

  All outstanding American Depositary Shares (ADSs) will be mandatorily exchanged for one ordinary share each.

• Trading Transition

  The last day of ADS trading on Nasdaq is expected to be April 17, 2026, with ordinary shares commencing trading on April 20, 2026, under the ticker ASND.

auto_awesomeAnalysis

This strategic move simplifies Ascendis Pharma's capital structure for U.S. investors by eliminating the American Depositary Share (ADS) program. The direct listing of ordinary shares on Nasdaq is anticipated to enhance liquidity, reduce administrative complexities and fees associated with ADSs, and potentially broaden the company's investor base. Investors currently holding ADSs will automatically receive ordinary shares, which will continue to trade under the existing ticker symbol ASND.